Background
Sample size
Example
Methods
Data sources
Statistical analysis
Results
Trials
Trial name | Trial population | Age range (years) | Outcome measures | No. of outcomes | Time points post-randomisation | No. of time points | No. of correlations | Sample size at baseline | Max Na | Reference | Year of publication | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Leg Ulcer | Leg ulcers | 32 to 97 | EQ-5D, SF-36 | 9 | 3, 12 months | 2 | 18 | 233 | 200 | [9] | 1998 |
2 | NAMEIT | Early severe rheumatoid arthritis | 18 to 75 | SF-36, SF-6D | 9 | 2, 4, 6, 8, 10, 12 months | 6 | 54 | 222 | 222 | [10] | 2000 |
3 | Homeopathy for CFS | Chronic fatigue syndrome (CFS) | 20 to 62 | MFI | 5 | 6 months | 1 | 5 | 103 | 85 | [11] | 2004 |
4 | Acupuncture | Low back pain | 20 to 64 | SF-36 | 8 | 3, 12, 24 months | 3 | 24 | 239 | 217 | [12] | 2005 |
5 | Knee Replacement | Osteoarthritis patients undergoing total knee replacement | 51 to 92 | SF-36, WOMAC | 14 | 3 months | 1 | 14 | 151 | 114 | [13] | 2005 |
6 | FED | Older (aged ≥ 65) hospitalised patients with acute illness | 65 to 93 | Barthel, SF-36 | 9 | 1.5, 6 months | 2 | 18 | 445 | 225 | [14] | 2006 |
7 | AIM-High | Malignant melanoma | 18 to 77 | EORTC QLQ-C30 | 15 | 6, 12, 18, 24 months | 4 | 60 | 444 | 392 | [15] | 2006 |
8 | PoNDER | New mothers | 18 to 45 | CORE-OM, EPDS,b SF-36, SF-6D | 9 | 4.5, 10.5, 16.5 months | 3 | 26 | 2659 | 2659 | [16] | 2009 |
9 | COPD | Chronic obstructive pulmonary disease (COPD) | 49 to 86 | EQ-5D, SF-36, SF-6D | 12 | 2, 6, 12, 18 months | 4 | 48 | 238 | 172 | [17] | 2010 |
10 | Corn Plasters | Foot corns | 18 to 90 | EQ-5D, EQ-5D VAS, VAS Pain | 3 | 3, 6, 9, 12 months | 4 | 12 | 201 | 182 | [18] | 2013 |
11 | PLINY | Independently living older people (aged ≥ 75) | 75 to 95 | EQ-5D, EQ-5D VAS, GSES, ONS Well-being, PHQ-9, SF-36 | 15 | 6 months | 1 | 15 | 157 | 56 | [19] | 2014 |
12 | 3Mg | Adults with acute severe asthma in the emergency department | 16 to 88 | EQ-5D | 1 | 1 month | 1 | 1 | 932 | 437 | [20] | 2014 |
13 | SELF | Shoulder rotator cuff tendinopathy | 23 to 83 | SPADI | 3 | 3, 6, 12 months | 3 | 9 | 85 | 59 | [6] | 2016 |
14 | BEADS | Post-stroke depression | 31 to 97 | EQ-5D, EQ-5D VAS, PHQ-9 | 3 | 6 months | 1 | 3 | 49 | 39 | [21] | 2016 |
15 | DiPALS | Amyotrophic lateral sclerosis (ALS) | 23 to 83 | EQ-5D, SAQLI, SF-36 | 13 | 2, 3, 6, 9, 12 months | 5 | 65 | 74 | 55 | [22] | 2016 |
16 | Lifestyle Matters | Independently living older people (aged ≥ 65) | 65 to 92 | EQ-5D, EQ-5D VAS, GSES, PHQ-9, SF-36 | 14 | 6, 24 months | 2 | 28 | 288 | 262 | [23] | 2017 |
17 | IPSU | Women with urinary incontinence and sexual dysfunction | 21 to 70 | EQ-5D, PISQ-31, SF-36 | 15 | 6 months | 1 | 15 | 107 | 66 | [24] | 2018 |
18 | POLAR | Lumbar radicular syndrome (LRS) | 23 to 71 | Back Pain VAS, EQ-5D, EQ-5D VAS, Leg Pain VAS, ODI | 5 | 1.5, 3, 6 months | 3 | 15 | 80 | 73 | [25] | 2018 |
19 | PRACTICE | COPD | 40 to 92 | EQ-5D, EQ-5D VAS | 2 | 0.25, 1, 3 months | 3 | 6 | 55 | 42 | [26] | 2018 |
20 | STEPWISE | Schizophrenia | 18 to 71 | B-IPQ, BPRS, EQ-5D, EQ-5D VAS, PHQ-9, RAND SF-36 | 14 | 3, 12 months | 2 | 28 | 412 | 358 | [27] | 2018 |
464 | 7173 | 5915 |
Outcome name | Trials | Score range | Correlations | Reference | |
---|---|---|---|---|---|
1 | B-IPQ | 1 | 0 to 10 | 2 | [28] |
2 | Back Pain VAS | 1 | 0 to 10 | 3 | [29] |
3 | Barthel score | 1 | 0 to 20 | 2 | [30] |
4 | BPRS | 1 | 0 to 126 | 2 | [31] |
5 | CORE Life functioning dimension | 1 | 0 to 4 | 3 | [32] |
6 | CORE Risk/harm dimension | 1 | 0 to 4 | 3 | |
7 | CORE Problems/symptoms dimension | 1 | 0 to 4 | 3 | |
8 | CORE Subjective well-being dimension | 1 | 0 to 4 | 3 | |
9 | CORE total score | 1 | 0 to 4 | 3 | |
10 | EORTC Appetite Loss | 1 | 0 to 100 | 4 | [33] |
11 | EORTC Cognitive Functioning | 1 | 0 to 100 | 4 | |
12 | EORTC Constipation | 1 | 0 to 100 | 4 | |
13 | EORTC Diarrhoea | 1 | 0 to 100 | 4 | |
14 | EORTC Dyspnoea | 1 | 0 to 100 | 4 | |
15 | EORTC Emotional Functioning | 1 | 0 to 100 | 4 | |
16 | EORTC Fatigue | 1 | 0 to 100 | 4 | |
17 | EORTC Financial Difficulties | 1 | 0 to 100 | 4 | |
18 | EORTC Insomnia | 1 | 0 to 100 | 4 | |
19 | EORTC Nausea | 1 | 0 to 100 | 4 | |
20 | EORTC Pain | 1 | 0 to 100 | 4 | |
21 | EORTC Physical Functioning | 1 | 0 to 100 | 4 | |
22 | EORTC QoL | 1 | 0 to 100 | 4 | |
23 | EORTC Role Functioning | 1 | 0 to 100 | 4 | |
24 | EORTC Social Functioning | 1 | 0 to 100 | 4 | |
25 | EPDS | 1 | 0 to 30 | 2 | [34] |
26 | EQ-5D Utility score | 12 | −0.56 to 1.00 | 29 | [35] |
27 | EQ-5D VAS | 8 | 0 to 100 | 21 | [36] |
28 | GSES | 2 | 10 to 40 | 3 | [37] |
29 | Leg Pain VAS | 1 | 0 to 10 | 3 | [29] |
30 | MFI General Fatigue | 1 | 4 to 20 | 1 | [38] |
31 | MFI Mental Fatigue | 1 | 4 to 20 | 1 | |
32 | MFI Physical Fatigue | 1 | 4 to 20 | 1 | |
33 | MFI Reduced Activity | 1 | 4 to 20 | 1 | |
34 | MFI Reduced Motivation | 1 | 4 to 20 | 1 | |
35 | ODI | 1 | 0 to 100 | 3 | [39] |
36 | ONS Well-Being | 1 | 0 to 40 | 1 | [40] |
37 | PHQ-9 | 4 | 0 to 27 | 6 | [41] |
38 | PISQ-31 Behaviour/Emotion | 1 | 0 to 61 | 1 | [42] |
39 | PISQ-31 Partner-Related Factor | 1 | 0 to 24 | 1 | |
40 | PISQ-31 Physical Factor | 1 | 0 to 40 | 1 | |
41 | PISQ-31 total score | 1 | 0 to 125 | 1 | |
42 | SF-36 General Health | 11 | 0 to 100 | 29 | [43] |
43 | SF-36 Mental Health | 11 | 1 to 100 | 29 | |
44 | SF-36 Pain | 11 | 1 to 100 | 29 | |
45 | SF-36 Physical Functioning | 11 | 1 to 100 | 29 | |
46 | SF-36 Role-Emotional | 11 | 1 to 100 | 29 | |
47 | SF-36 Role-Physical | 11 | 1 to 100 | 29 | |
48 | SF-36 Social Functioning | 11 | 1 to 100 | 29 | |
49 | SF-36 Vitality | 11 | 1 to 100 | 29 | |
50 | SF-36 Health Change | 1 | 1 to 100 | 2 | |
51 | SF-36 Mental Component Summary | 7 | NBS | 17 | [44] |
52 | SF-36 Physical Component Summary | 7 | NBS | 17 | |
53 | SF-6D | 4 | 0.29 to 1.00 | 14 | [45] |
54 | Sleep Apnoea QoL | 1 | 1 to 7 | 5 | [46] |
55 | SPADI Disability | 1 | 0 to 100 | 3 | [47] |
56 | SPADI Pain | 1 | 0 to 100 | 3 | |
57 | SPADI total score | 1 | 0 to 100 | 3 | |
58 | VAS Pain | 1 | 0 to 10 | 4 | [48] |
59 | WOMAC Pain | 1 | 0 to 20 | 1 | [49] |
60 | WOMAC Physical Function | 1 | 0 to 68 | 1 | |
61 | WOMAC Stiffness | 1 | 0 to 8 | 1 |
Correlation
Trial name | Pearson baseline to post-randomisation follow-up correlation | |||||
---|---|---|---|---|---|---|
Mean | Median | No. of correlations | SD | Minimum | Maximum | |
Leg Ulcer | 0.48 | 0.5 | N = 18 | 0.13 | 0.23 | 0.71 |
NAMEIT | 0.46 | 0.46 | N = 54 | 0.1 | 0.21 | 0.63 |
Homeopathy for CFS | 0.5 | 0.53 | N = 5 | 0.19 | 0.18 | 0.65 |
Acupuncture | 0.44 | 0.45 | N = 24 | 0.12 | 0.2 | 0.62 |
Knee Replacement | 0.45 | 0.48 | N = 14 | 0.16 | 0.09 | 0.65 |
FED | 0.5 | 0.56 | N = 18 | 0.12 | 0.32 | 0.7 |
AIM-High | 0.46 | 0.49 | N = 60 | 0.14 | 0.16 | 0.74 |
PoNDER | 0.44 | 0.47 | N = 26 | 0.11 | 0.19 | 0.58 |
COPD | 0.53 | 0.54 | N = 48 | 0.08 | 0.37 | 0.68 |
Corn Plaster | 0.45 | 0.45 | N = 12 | 0.06 | 0.33 | 0.53 |
PLINY | 0.67 | 0.74 | N = 15 | 0.15 | 0.41 | 0.87 |
3Mg | 0.39 | 0.39 | N = 1 | - | 0.39 | 0.39 |
SELF | 0.44 | 0.44 | N = 9 | 0.07 | 0.31 | 0.54 |
BEADS | 0.46 | 0.53 | N = 3 | 0.3 | 0.14 | 0.71 |
DiPALS | 0.54 | 0.57 | N = 65 | 0.18 | 0.01 | 0.91 |
Lifestyle Matters | 0.66 | 0.64 | N = 28 | 0.11 | 0.45 | 0.88 |
IPSU | 0.57 | 0.63 | N = 15 | 0.13 | 0.34 | 0.73 |
POLAR | 0.32 | 0.36 | N = 15 | 0.14 | 0.04 | 0.53 |
PRACTICE | 0.36 | 0.38 | N = 6 | 0.36 | −0.13 | 0.79 |
STEPWISE | 0.53 | 0.56 | N = 28 | 0.13 | 0.24 | 0.72 |
Totala | 0.5 | 0.51 | N = 464 | 0.15 | −0.13 | 0.91 |
Post-randomisation follow-up time point (months) | Pearson baseline to post-randomisation follow-up correlation | |||||
---|---|---|---|---|---|---|
Mean | Median | SD | Minimum | Maximum | No. of correlations | |
0.25 | 0.48 | 0.48 | 0.44 | 0.17 | 0.79 | 2 |
1 | 0.37 | 0.39 | 0.28 | 0.09 | 0.64 | 3 |
1.5 | 0.49 | 0.45 | 0.12 | 0.33 | 0.70 | 14 |
2 | 0.55 | 0.56 | 0.12 | 0.26 | 0.82 | 34 |
3 | 0.48 | 0.50 | 0.15 | −0.13 | 0.72 | 71 |
4 | 0.48 | 0.49 | 0.09 | 0.35 | 0.63 | 9 |
4.5 | 0.48 | 0.52 | 0.09 | 0.32 | 0.58 | 9 |
6 | 0.54 | 0.55 | 0.16 | 0.04 | 0.88 | 121 |
8 | 0.43 | 0.44 | 0.13 | 0.21 | 0.58 | 9 |
9 | 0.62 | 0.62 | 0.16 | 0.38 | 0.91 | 16 |
10 | 0.45 | 0.43 | 0.08 | 0.34 | 0.58 | 9 |
10.5 | 0.42 | 0.47 | 0.12 | 0.19 | 0.54 | 9 |
12 | 0.46 | 0.48 | 0.14 | 0.01 | 0.72 | 86 |
16.5 | 0.41 | 0.42 | 0.12 | 0.23 | 0.57 | 8 |
18 | 0.47 | 0.49 | 0.13 | 0.16 | 0.67 | 27 |
24 | 0.51 | 0.53 | 0.15 | 0.17 | 0.84 | 37 |
Outcome | Pearson baseline to post-randomisation follow-up correlation | |||||
---|---|---|---|---|---|---|
Mean | Median | SD | Minimum | Maximum | No. of correlations | |
B-IPQ | 0.6 | 0.6 | 0 | 0.6 | 0.61 | 2 |
BACK PAIN | 0.24 | 0.19 | 0.11 | 0.17 | 0.37 | 3 |
Barthel Score | 0.53 | 0.53 | 0.1 | 0.45 | 0.6 | 2 |
BPRS | 0.57 | 0.57 | 0.12 | 0.49 | 0.65 | 2 |
CORE Functioning Dimension | 0.56 | 0.57 | 0.02 | 0.54 | 0.58 | 3 |
CORE Risk Dimension | 0.26 | 0.27 | 0.07 | 0.19 | 0.32 | 3 |
CORE Symptoms Dimension | 0.5 | 0.49 | 0.03 | 0.47 | 0.54 | 3 |
CORE Total Score | 0.55 | 0.53 | 0.03 | 0.53 | 0.58 | 3 |
CORE Well Being Dimension | 0.5 | 0.49 | 0.03 | 0.47 | 0.53 | 3 |
EORTC Appetite Loss | 0.29 | 0.3 | 0.09 | 0.21 | 0.37 | 4 |
EORTC Cognitive Functioning | 0.49 | 0.49 | 0.08 | 0.4 | 0.59 | 4 |
EORTC Constipation | 0.39 | 0.4 | 0.08 | 0.3 | 0.48 | 4 |
EORTC Diarrhoea | 0.25 | 0.27 | 0.07 | 0.16 | 0.32 | 4 |
EORTC Dyspnoea | 0.43 | 0.44 | 0.06 | 0.35 | 0.49 | 4 |
EORTC Emotional Functioning | 0.51 | 0.5 | 0.06 | 0.46 | 0.6 | 4 |
EORTC Fatigue | 0.56 | 0.56 | 0.06 | 0.49 | 0.63 | 4 |
EORTC Financial Difficulties | 0.63 | 0.62 | 0.07 | 0.56 | 0.74 | 4 |
EORTC Insomnia | 0.44 | 0.49 | 0.12 | 0.26 | 0.52 | 4 |
EORTC Nausea | 0.21 | 0.18 | 0.06 | 0.16 | 0.3 | 4 |
EORTC Pain | 0.48 | 0.48 | 0.08 | 0.39 | 0.58 | 4 |
EORTC Physical Functioning | 0.59 | 0.58 | 0.07 | 0.52 | 0.68 | 4 |
EORTC QoL | 0.55 | 0.57 | 0.08 | 0.44 | 0.61 | 4 |
EORTC Role Functioning | 0.54 | 0.54 | 0.04 | 0.5 | 0.59 | 4 |
EORTC Social Functioning | 0.51 | 0.5 | 0.06 | 0.43 | 0.59 | 4 |
EPDS | 0.49 | 0.49 | 0.04 | 0.47 | 0.52 | 2 |
EQ-5D Utility Score | 0.55 | 0.54 | 0.13 | 0.32 | 0.87 | 29 |
EQ-5D VAS | 0.41 | 0.46 | 0.2 | −0.13 | 0.67 | 21 |
GSES | 0.52 | 0.56 | 0.08 | 0.44 | 0.58 | 3 |
LEG PAIN | 0.16 | 0.11 | 0.16 | 0.04 | 0.34 | 3 |
MFI General Fatigue | 0.18 | 0.18 | NA | 0.18 | 0.18 | 1 |
MFI Mental Fatigue | 0.53 | 0.53 | NA | 0.53 | 0.53 | 1 |
MFI Physical Fatigue | 0.5 | 0.5 | NA | 0.5 | 0.5 | 1 |
MFI Reduced Activity | 0.65 | 0.65 | NA | 0.65 | 0.65 | 1 |
MFI Reduced Motivation | 0.61 | 0.61 | NA | 0.61 | 0.61 | 1 |
ODI | 0.36 | 0.36 | 0.05 | 0.31 | 0.41 | 3 |
ONS Well-Being | 0.62 | 0.62 | NA | 0.62 | 0.62 | 1 |
PHQ9 | 0.66 | 0.66 | 0.08 | 0.53 | 0.76 | 6 |
PISQ-31 Behaviour/Emotion | 0.73 | 0.73 | NA | 0.73 | 0.73 | 1 |
PISQ-31 Partner Related Factor | 0.63 | 0.63 | NA | 0.63 | 0.63 | 1 |
PISQ-31 Physical Factor | 0.35 | 0.35 | NA | 0.35 | 0.35 | 1 |
PISQ-31 Total Score | 0.62 | 0.62 | NA | 0.62 | 0.62 | 1 |
SF-36 General Health | 0.6 | 0.58 | 0.08 | 0.49 | 0.79 | 29 |
SF-36 Mental Component Summary | 0.54 | 0.55 | 0.12 | 0.33 | 0.79 | 17 |
SF-36 Mental Health | 0.57 | 0.57 | 0.11 | 0.37 | 0.83 | 27 |
SF-36 Pain | 0.49 | 0.51 | 0.13 | 0.2 | 0.71 | 29 |
SF-36 Physical Component Summary | 0.56 | 0.6 | 0.21 | 0.14 | 0.84 | 17 |
SF-36 Physical Functioning | 0.64 | 0.63 | 0.17 | 0.01 | 0.91 | 29 |
SF-36 Role-Emotional | 0.42 | 0.43 | 0.11 | 0.12 | 0.68 | 31 |
SF-36 Role-Physical | 0.39 | 0.35 | 0.12 | 0.21 | 0.67 | 29 |
SF-36 Social Functioning | 0.44 | 0.45 | 0.1 | 0.24 | 0.63 | 29 |
SF-36 Vitality | 0.55 | 0.53 | 0.1 | 0.43 | 0.82 | 29 |
SF-36 Health Change | 0.32 | 0.32 | 0.11 | 0.24 | 0.4 | 2 |
SF-6D | 0.5 | 0.48 | 0.09 | 0.37 | 0.64 | 14 |
Sleep Apnoea QoL | 0.56 | 0.6 | 0.12 | 0.35 | 0.65 | 5 |
SPADI | 0.47 | 0.47 | 0.03 | 0.44 | 0.5 | 3 |
SPADI Disability | 0.49 | 0.51 | 0.06 | 0.43 | 0.54 | 3 |
SPADI Pain | 0.36 | 0.38 | 0.05 | 0.31 | 0.4 | 3 |
VAS Pain | 0.41 | 0.41 | 0.07 | 0.33 | 0.48 | 4 |
WOMAC Pain | 0.26 | 0.26 | NA | 0.26 | 0.26 | 1 |
WOMAC Physical Function | 0.46 | 0.46 | NA | 0.46 | 0.46 | 1 |
WOMAC Stiffness | 0.09 | 0.09 | NA | 0.09 | 0.09 | 1 |